Drugs / IBI3003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07336472 | Sep 2026 → Jun 2027 expected | plasma cell myeloma | Fortvita Biologics (USA)Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06083207 | Jul 2024 → Oct 2026 expected | plasma cell myeloma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07623798 | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma innoventbio.com ↗
At the RP2D, IBI3003 demonstrated rapid, deep, and durable response signals, particularly in heavily pretreated, high-risk patients with extramedullary disease. |
| 2026-01-27 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma innoventbio.com ↗
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). |
| 2025-12-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma innoventbio.com ↗
IBI3003 demonstrated favorable tolerability and a manageable safety profile. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | Innovent Biologics (Suzhou) Co. Ltd. | 2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma innoventbio.com ↗ |
| 2026-06-22 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma innoventbio.com ↗ |
| 2026-01-27 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma innoventbio.com ↗ |
| 2025-12-08 | Innovent Biologics (Suzhou) Co. Ltd. | ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma innoventbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06083207 ↗ |